
MTNB P/E Ratio
P/E Ratio as of Jun 13, 2025: -0.21
Average-0.2095
Median-0.2100
Minimum-0.2600
Maximum-0.1900
-0.21
Past Month-0.04 (23.53%)
The P/E ratio for MTNB is -0.21 as of Jun 13, 2025. This represents a decrease of -55.32% compared to its 12-month average P/E ratio of -0.47. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Matinas BioPharma Hlds P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Matinas BioPharma Hlds’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Matinas BioPharma Hlds to industry peers.
Matinas BioPharma Hlds P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Matinas BioPharma Hlds’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Matinas BioPharma Hlds to industry peers.
MTNB P/E Ratio Insights
See Matinas BioPharma Hlds’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in MTNB
Order type
Buy in
Order amount
Est. shares
0 shares
MTNB P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jun 2, 2025 | $0.82 | -0.21 |
May 1, 2025 | $0.62 | -0.12 |
Apr 1, 2025 | $0.57 | -0.13 |
Mar 3, 2025 | $0.55 | -0.12 |
Feb 3, 2025 | $0.574 | -0.13 |
Jan 2, 2025 | $0.588 | -0.13 |
MTNB End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -0.21 | +90.91% |
2024 | -0.11 | -95.02% |
2023 | -2.21 | -50.89% |
2022 | -4.50 | -49.94% |
2021 | -8.99 | -22.03% |
2020 | -11.53 | — |
FAQs About Matinas BioPharma Hlds (MTNB) P/E ratio
The latest P/E ratio of MTNB is -0.21, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Matinas BioPharma Hlds’s last 12-month average P/E ratio is -0.47, compared to its current P/E ratio of -0.21. This reflects a decrease of -55.32%.
Matinas BioPharma Hlds’s current P/E ratio of -0.21 is lower than its last 12-month average P/E of -0.47. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Matinas BioPharma Hlds’s average P/E ratio over the last 3 years is -2.92. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Matinas BioPharma Hlds’s average P/E ratio over the last 5 years is -4.93. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.